Intracerebroventricular Dopamine for Parkinson's Disease
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.
Fabbrini A, Guerra A J Exp Pharmacol. 2021; 13:469-485.
PMID: 33953618 PMC: 8092630. DOI: 10.2147/JEP.S265282.
References
1.
de Yebenes J, Fahn S, Lovelle S, Jackson-Lewis V, Jorge P, Mena M
. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. Mov Disord. 1987; 2(3):143-58.
DOI: 10.1002/mds.870020302.
View
2.
Venna N, Sabin T, Ordia J, MARK V
. Treatment of severe Parkinson's disease by intraventricular injection of dopamine. Appl Neurophysiol. 1984; 47(1-2):62-4.
DOI: 10.1159/000101204.
View
3.
Gershanik O, Jenner P
. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol. 2012; 19(12):1502-8.
DOI: 10.1111/j.1468-1331.2011.03593.x.
View
4.
Laloux C, Gouel F, Lachaud C, Timmerman K, Do Van B, Jonneaux A
. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. Neurobiol Dis. 2017; 103:24-31.
DOI: 10.1016/j.nbd.2017.03.013.
View
5.
Horne M, BUTLER E, GILLIGAN B, Wodak J, Stark R, Brazenor G
. Intraventricular infusion of Dopamine in Parkinson's disease. Ann Neurol. 1989; 26(6):792-4.
DOI: 10.1002/ana.410260620.
View